Immunoassay Detects Severe Fever with Thrombocytopenia Syndrome Virus
|
By LabMedica International staff writers Posted on 25 Apr 2016 |

Image: A scanning electron micrograph (SEM) of severe fever with thrombocytopenia syndrome virus (Photo courtesy of the Japanese National Institute of Infectious Diseases).
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease with a high case fatality rate, and is caused by the SFTS virus (SFTSV) and the disease is endemic to China, South Korea, and Japan.
The viral ribonucleic acid (RNA) level in sera of patients with SFTS is known to be strongly associated with outcomes and therefore virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas.
Scientists at the Japanese National Institute of Infectious Diseases (Tokyo, Japan) and their colleagues collected 63 serum samples from 55 acute phase patients suspected of SFTS in Japan. Viral gene detection by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and viral antibody detection by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and/or indirect fluorescent antibody (IFA) were conducted to diagnose SFTS. From 55 patients, 34 of these were diagnosed as having SFTSV. Serum samples obtained from 18 healthy donors were used to establish the cut-off value of the IgG ELISA. Serum samples used for IgG ELISA were inactivated under the UV light in the biosafety cabinet for one hour.
The investigators generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture ELISAs were read using an optical density at 405 nm (OD405) was measured against a reference of 490 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories Inc.; Hercules, CA, USA). The Ag-capture system was capable of detecting at least 350 to 1,220 50% Tissue Culture Infective Dose (TCID50)/100 μL/well from the culture supernatants of various SFTSV strains.
All 24 serum samples (100%) containing high copy numbers of viral RNA more than 105 copies/mL) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (less than 105 copies/mL) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA- negative 12 samples, nine (75%) were positive for IgG antibodies against SFTSV. The authors conclude that the newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. The study was published on April 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.
The viral ribonucleic acid (RNA) level in sera of patients with SFTS is known to be strongly associated with outcomes and therefore virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas.
Scientists at the Japanese National Institute of Infectious Diseases (Tokyo, Japan) and their colleagues collected 63 serum samples from 55 acute phase patients suspected of SFTS in Japan. Viral gene detection by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and viral antibody detection by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and/or indirect fluorescent antibody (IFA) were conducted to diagnose SFTS. From 55 patients, 34 of these were diagnosed as having SFTSV. Serum samples obtained from 18 healthy donors were used to establish the cut-off value of the IgG ELISA. Serum samples used for IgG ELISA were inactivated under the UV light in the biosafety cabinet for one hour.
The investigators generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture ELISAs were read using an optical density at 405 nm (OD405) was measured against a reference of 490 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories Inc.; Hercules, CA, USA). The Ag-capture system was capable of detecting at least 350 to 1,220 50% Tissue Culture Infective Dose (TCID50)/100 μL/well from the culture supernatants of various SFTSV strains.
All 24 serum samples (100%) containing high copy numbers of viral RNA more than 105 copies/mL) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (less than 105 copies/mL) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA- negative 12 samples, nine (75%) were positive for IgG antibodies against SFTSV. The authors conclude that the newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. The study was published on April 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Japanese National Institute of Infectious Diseases
Bio-Rad Laboratories
Latest Microbiology News
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more




.jpg)



